Respiri
Sydney, Australia· Est.
Respiri provides a remote wheeze‑detection platform that lets health systems monitor and intervene in asthma and COPD patients at scale.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
AI Company Overview
Respiri provides a remote wheeze‑detection platform that lets health systems monitor and intervene in asthma and COPD patients at scale.
RespiratoryPulmonaryChronic Disease Management
Technology Platform
Proprietary acoustic sensor suite combined with AI‑driven signal processing and a HIPAA‑compliant SaaS dashboard for real‑time wheeze detection and RPM workflow integration.
Opportunities
Expansion of RPM programs into broader chronic disease areas, international regulatory approvals, and deeper integration with EHR ecosystems.
Risk Factors
Dependence on CMS reimbursement policy stability and competitive pressure from larger telehealth and device manufacturers.
Competitive Landscape
Key competitors include Propeller Health, Cohero Health, and ResMed; Respiri differentiates by offering the only FDA‑cleared remote wheeze detection technology within its RPM platform.